Cargando…
PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429717/ http://dx.doi.org/10.1097/01.HS9.0000975832.38492.3b |
| _version_ | 1785090781642489856 |
|---|---|
| author | Novelli, Silvana Risal, Ashish Namuduri, Manjusha Cai, Jingxian Ufkin, Melanie Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Iskierka-Jażdżewska, Elżbieta |
| author_facet | Novelli, Silvana Risal, Ashish Namuduri, Manjusha Cai, Jingxian Ufkin, Melanie Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Iskierka-Jażdżewska, Elżbieta |
| author_sort | Novelli, Silvana |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429717 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297172023-08-17 PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) Novelli, Silvana Risal, Ashish Namuduri, Manjusha Cai, Jingxian Ufkin, Melanie Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Iskierka-Jażdżewska, Elżbieta Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429717/ http://dx.doi.org/10.1097/01.HS9.0000975832.38492.3b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Novelli, Silvana Risal, Ashish Namuduri, Manjusha Cai, Jingxian Ufkin, Melanie Zhu, Min Mukherjee, Sushmita Brouwer-Visser, Jurriaan Chaudhry, Aafia Mohamed, Hesham Ambati, Srikanth Iskierka-Jażdżewska, Elżbieta PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) |
| title | PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) |
| title_full | PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) |
| title_fullStr | PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) |
| title_full_unstemmed | PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) |
| title_short | PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2) |
| title_sort | pb2275: trial in progress: phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (olympia-2) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429717/ http://dx.doi.org/10.1097/01.HS9.0000975832.38492.3b |
| work_keys_str_mv | AT novellisilvana pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT risalashish pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT namudurimanjusha pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT caijingxian pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT ufkinmelanie pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT zhumin pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT mukherjeesushmita pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT brouwervisserjurriaan pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT chaudhryaafia pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT mohamedhesham pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT ambatisrikanth pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 AT iskierkajazdzewskaelzbieta pb2275trialinprogressphase3trialevaluatingtheefficacyandsafetyofodronextamabpluschemotherapyversusrituximabpluschemotherapyinpreviouslyuntreatedfollicularlymphomaolympia2 |